Navigation Links
Sangart Announces Closing of $50 Million Series G Financing
Date:4/19/2011

SAN DIEGO, April 19, 2011 /PRNewswire/ -- Sangart, Inc., today announced that it recently received more than $50 million in new equity funding from existing investors, led by Leucadia National Corporation. The most recent investment brings the total funding raised by the company since its inception in 1998 to more than $230 million. This financing round also included warrants which, if exercised, could provide up to an additional $50 million in future funding.

Funds raised in this Series G round will be used to advance the development of the MP4OX product in severe traumatic hemorrhage and the MP4CO product in sickle cell disease. MP4OX is an investigational biopharmaceutical designed to enhance the perfusion of oxygen-deprived (ischemic) tissues and provide targeted oxygen delivery in the capillaries. MP4CO is an investigational biopharmaceutical designed to deliver therapeutic levels of carbon monoxide (CO) to patients suffering from a sickle cell crisis.

"We are encouraged by this level of support from our existing investors, who recognize the clinical potential of our products," said Brian O'Callaghan, President and CEO of Sangart. "This funding will allow us to continue advancing the development of our medicines and get them as quickly as possible to patients in need. We continue to see promise in our MP4-based medicines in the treatment of patients who experience an acute traumatic injury and in patients with sickle cell disease suffering from a vaso-occlusive crisis."

About MP4Sangart's product platform is based on the MP4 molecule, an investigational biopharmaceutical product designed to enhance the perfusion of oxygen-deprived (ischemic) tissues and provide targeted oxygen delivery in the capillaries. Using a novel pegylation approach, Sangart produces the MP4 molecule designed at the optimal oxygen affinity, diffusion potential and molecular size to perfuse capillaries and target oxygen delivery to tissues specifically at risk of
'/>"/>

SOURCE Sangart, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2

Related medicine technology :

1. Sangart, Inc. Receives U.S. Orphan Drug Designation for use of MP4CO in Patients with Sickle Cell Disease
2. Sangart, Inc. Initiates Phase IIa Study of Oxygen Therapeutic Agent MP4OX in Severe Trauma Patients With Hemorrhagic Shock
3. Sangart Completes Enrollment in Phase III Study of Its Novel Blood Substitute Hemospan
4. Independent Data Safety Monitoring Board Recommends Continuation of Sangarts Pivotal Phase III Trials of Hemospan(R) Following Second Interim Review
5. Sangart, Inc. Initiates Dosing in Phase II Study of Hemospan(R) in Chronic Critical Limb Ischemia
6. MiMedx Group, Inc. Announces Release Date for First Quarter Results
7. Awarepoint Corporation Announces Acquisition of PCTS
8. Omeros Announces Publication of MASP-2 Data in Proceedings of the National Academy of Sciences
9. Cumberland Pharmaceuticals Announces New Product Addition With Hepatoren™ (ifetroban) Injection
10. CryoLife Announces Release Date and Teleconference Call Details for 2011 First Quarter Financial Results
11. Amicus Therapeutics Announces Transition of John F. Crowley from Chairman and Chief Executive Officer to Executive Chairman
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/19/2014)... , Dec. 18, 2014   Aratana ... a biopharmaceutical company focused on the licensing, development ... today announced positive results from its pivotal field ... for treating pain in dogs with osteoarthritis.  In ... pain assessment scores that were statistically significant compared ...
(Date:12/17/2014)... 17, 2014 Los beneficios y ... alto nivel de gasto en investigación y desarrollo   ... el 30 de septiembre de 2014) ZEISS aumentó sus ... de euros (año anterior: 4.190 millones de euros) a ... ganancias (EBIT) crecieron un 14 por ciento, a 360 ...
(Date:12/17/2014)... , Dec. 17, 2014 With ... (MRI), the MRI market is seeing new growth, ... breast MRI scans account for the majority of ... higher resolution of images, which are creating opportunities for ... (MRI) market is growing at a rate of ...
Breaking Medicine Technology:Aratana Therapeutics Announces Positive Top-Line Results from AT-001 Pivotal Field Study in Client-Owned Dogs with Osteoarthritis 2Aratana Therapeutics Announces Positive Top-Line Results from AT-001 Pivotal Field Study in Client-Owned Dogs with Osteoarthritis 3Aratana Therapeutics Announces Positive Top-Line Results from AT-001 Pivotal Field Study in Client-Owned Dogs with Osteoarthritis 4Aratana Therapeutics Announces Positive Top-Line Results from AT-001 Pivotal Field Study in Client-Owned Dogs with Osteoarthritis 5ZEISS confirma su posición en un entorno difícil 2Kalorama: 3T Advancements Bringing New Growth to the MRI Market 2Kalorama: 3T Advancements Bringing New Growth to the MRI Market 3
... Nov. 16, 2011 Reportlinker.com announces that a ... catalogue: X-ray Equipment - Top ... This package contains top 5 ... China, Japan, India, South Koera, and Indonesia. ...
... Nov. 16, 2011 Reportlinker.com announces ... is available in its catalogue: ... Angiogenesis and Peptides ... triple analysis focuses on cancer drug ...
Cached Medicine Technology:X-ray Equipment - Top 5 Asian Markets 2Triple Analysis: Prostate Cancer, Angiogenesis and Peptides 2Triple Analysis: Prostate Cancer, Angiogenesis and Peptides 3Triple Analysis: Prostate Cancer, Angiogenesis and Peptides 4Triple Analysis: Prostate Cancer, Angiogenesis and Peptides 5
(Date:12/21/2014)... New York (PRWEB) December 21, 2014 ... and other product liability claims involving a class ... mimetics continue to move forward in a federal ... Southern District of California, Bernstein Liebhard LLP reports. ... Court has established a data cut-off date of ...
(Date:12/21/2014)... San Francisco, California (PRWEB) December 21, 2014 ... announces his search for Vintage 1967 Jm Morrison and the ... D.C. concert posters. This would also be the only ... live. The concert was on Nov. 25, 1967. According ... in Washington D.C. They did play the Alexandria Roller ...
(Date:12/21/2014)... 2014 As testosterone therapy lawsuit ... stroke and blood clots from using testosterone products such ... study shows that the male hormone testosterone may increase ... study published in the Proceedings of the National Academy ... a group of male rats with naturally occurring colon ...
(Date:12/20/2014)... BambooIndustry.com is a leading eco-friendly ... announced its bamboo flooring promotion for the coming ... certified suppliers, and offers the best bamboo products ... current promotion, all customers can enjoy a special ... they know BambooIndustry.com from press releases. , The ...
(Date:12/20/2014)... December 20, 2014 DePuy Pinnacle ... metal-on-metal version of the artificial hip system was ... and federal courts, Bernstein Liebhard LLP reports. According ... County Superior Court on December 2nd, counsel in ... deposition of plaintiffs on November 19, 2014, with ...
Breaking Medicine News(10 mins):Health News:Byetta Lawsuit News: New Order Issued in Federal Incretin Mimetics Litigation, Bernstein Liebhard LLP Report 2Health News:Byetta Lawsuit News: New Order Issued in Federal Incretin Mimetics Litigation, Bernstein Liebhard LLP Report 3Health News:Byetta Lawsuit News: New Order Issued in Federal Incretin Mimetics Litigation, Bernstein Liebhard LLP Report 4Health News:New Low Testosterone Therapy Study Shows Male Hormone Testosterone May Contribute To Colon Cancer Reports Wright & Schulte LLC 2Health News:New Low Testosterone Therapy Study Shows Male Hormone Testosterone May Contribute To Colon Cancer Reports Wright & Schulte LLC 3Health News:New Low Testosterone Therapy Study Shows Male Hormone Testosterone May Contribute To Colon Cancer Reports Wright & Schulte LLC 4Health News:Eco-friendy Bamboo Flooring Manufacturer BambooIndustry.com Introduces Its Bamboo Flooring Promotion for 2015 2Health News:New Jersey Court Overseeing DePuy Pinnacle Hip Lawsuits Issues New Order, Bernstein Liebhard LLP Reports 2Health News:New Jersey Court Overseeing DePuy Pinnacle Hip Lawsuits Issues New Order, Bernstein Liebhard LLP Reports 3Health News:New Jersey Court Overseeing DePuy Pinnacle Hip Lawsuits Issues New Order, Bernstein Liebhard LLP Reports 4
... Administrative Services to begin operations in Seattle , ... Employee Benefits, a national carrier of life and disability ... a new Administrative Services department in Seattle, Wa. , ... acquisition of certain capabilities, technology assets, and employees of ...
... best way to avoid deep vein thrombosis, report says ... no proof that genetic testing can help prevent the ... new U.S. government report shows. , The presence of ... G20210A can signal continued risk of blood clots, according ...
... with, study finds , TUESDAY, June 16 (HealthDay News) --Being ... doesn,t mean you,re doomed to have it, a long-term study ... pressure is affected by genes," said Dr. Nora Franceschini, an ... and lead author of a report on the study. "It,s ...
... to Receive Up to $400,000 in Funding - Application ... June 16 The GlaxoSmithKline IMPACT Awards target community-based ... Up to ten organizations in Berks, Bucks, Chester, ... awarded $40,000 each. The awards are bestowed upon ...
... Uses "Pop Culture Moment" to Advocate for Safe RN Staffing Levels ... The three nursing organizations at the heart of the newly ... advertising campaign in conjunction with the debut of HawthoRNe, ... nurse characters. The ad can be viewed here: ...
... Technology announced the release of The Observer(R) XT 9.0, ... release, Noldus announced the launch of Pocket Observer 3.0. ... handheld computer, making on-site research easy. , ... in more than 2000 scientific publications, The Observer XT ...
Cached Medicine News:Health News:Assurant Employee Benefits Adds New Voluntary Capabilities 2Health News:No Benefit in Testing for Genes Linked to Leg Clots 2Health News:Lifestyle May Counter Blood Pressure Genes 2Health News:Lifestyle May Counter Blood Pressure Genes 3Health News:GlaxoSmithKline 13th Annual IMPACT Awards Seek Nonprofits Providing Access to Healthcare 2Health News:National Nurses Movement Launches Ad Campaign for Nurse TV Shows 2Health News:Noldus Announces The Observer XT 9.0 2
The GC OIA test is a rapid assay for the diagnosis of gonorrhea. Thermo solved the challenge of developing a specific rapid assay for Neisseria gonorrhea by using the proprietary ribosomal protein, ...
... FLU OIA test is a high performance ... Influenza A and B with a simple, ... just over 15 minutes. Assay advantages include ... and performance equivalent to 14-day viral culture ...
... The CHLAYMDIA OIA test delivers 100% ... results in 19 minutes. With ... not returning for follow-up, this assay ... which can contribute to detection and ...
... Botox therapy and nerve block procedures, ... needle has a precisely machined Trocar ... an attached 61-cm (24-in) lead wire. ... Single patient use only. A starter ...
Medicine Products: